Form 8-K - Current report:
SEC Accession No. 0001159036-23-000047
Filing Date
2023-08-08
Accepted
2023-08-08 16:06:31
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20230808.htm   iXBRL 8-K 34015
2 EX-99.1 ex991q220238-k.htm EX-99.1 214288
6 GRAPHIC halozymea23.jpg GRAPHIC 701236
  Complete submission text file 0001159036-23-000047.txt   1337100

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20230808.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20230808_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20230808_pre.xml EX-101.PRE 12522
8 EXTRACTED XBRL INSTANCE DOCUMENT halo-20230808_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 231151217
SIC: 2836 Biological Products, (No Diagnostic Substances)